How to manage poor mobilizers for high dose chemotherapy and autologous stem cell transplantation?

Atilla P. A., Ozturk S. M. B., DEMİRER T.

TRANSFUSION AND APHERESIS SCIENCE, cilt.56, sa.2, ss.190-198, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 56 Sayı: 2
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1016/j.transci.2016.11.005
  • Dergi Adı: TRANSFUSION AND APHERESIS SCIENCE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.190-198
  • Anahtar Kelimeler: Autologous hematopoietic stem cell transplantation, Poor mobilizers, Plerixafor, Chemotherapy, G-CSF, COLONY-STIMULATING FACTOR, BLOOD PROGENITOR CELLS, TOTAL-BODY IRRADIATION, NON-HODGKINS-LYMPHOMA, PLUS G-CSF, SYNGENEIC MARROW TRANSPLANTATION, CHRONIC MYELOGENOUS LEUKEMIA, LARGE-VOLUME LEUKAPHERESIS, FACTOR RHG-CSF, HEMATOPOIETIC STEM
  • Ankara Üniversitesi Adresli: Evet

Özet

Today, peripheral blood stem cells are the preferred source of stem cells over bone marrow. Therefore, mobilization plays a crutial role in successful autologous stem cell transplantation. Poor mobilization is generally defined as failure to achieve the target level of at least 2 x 10(6) CD34(+) cells/kg body weight. There are several strategies to overcome poor mobilization: 1) Larger volume Leukapheresis (LVL) 2) Re-mobilization 3) Plerixafor 4) CM+ Plerixafor (P)+G-CSF and 5) Bone Marrow Harvest. In this review, the definitions of successful and poor mobilization are discussed. Management strategies for poor mobilization are defined. The recent research on new agents are included. (C) 2016 Elsevier Ltd. All rights reserved.